TWO · 6586.TWO
CHO Pharma, Inc.
NT$100.00-NT$3.50 (-3.38%)
CHO Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.66% below the high.
Loading market information…
TAI · 4164.TW · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
CHC Healthcare Group’s quoted price sits in the lower half of its reported 52-week range, 42.1% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
CHC Healthcare Group’s forward annual dividend is NT$1.11 per share, paid annual. The forward yield is 4.23% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
CHC Healthcare Group’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of NT$0.42. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow CHC Healthcare Group’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in Taipei, Taiwan, in 1977, the CHC Healthcare Group delivers a wide array of healthcare management services both within Taiwan and globally. Its core activities involve the distribution, installation, maintenance, and leasing of medical equipment. Furthermore, the company extends its expertise to include business management consulting, educational programs, elder care provisions, and radiation sterilization operations. The specialized equipment it provides serves key medical fields such as radiation oncology, neurology, medical imaging, ophthalmology, and surgery.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:28 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | May 7, 2025 | NT$0.05-86.84% vs estimate | NT$1.01B+15.0% vs estimate |
|---|
| Q4 2024 | Mar 12, 2025 | NT$0.27-41.3% vs estimate | NT$1.02B+2.66% vs estimate |
|---|
| Q3 2024 | Nov 6, 2024 | NT$0.50+11.11% vs estimate | NT$963.05M-0.1% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$100.00-NT$3.50 (-3.38%)
CHO Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.66% below the high.
NT$12.80-NT$0.55 (-4.12%)
Acepodia, Inc.’s quoted price sits in the lower half of its reported 52-week range, 26.44% below the high.
NT$17.20-NT$0.30 (-1.71%)
Adimmune Corporation’s quoted price sits in the lower half of its reported 52-week range, 23.56% below the high.
NT$104.50-NT$3.00 (-2.79%)
Bioteque Corporation’s quoted price sits in the lower half of its reported 52-week range, 20.83% below the high.
NT$74.00-NT$3.30 (-4.27%)
Medeon Biodesign, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.78% below the high.
NT$127.00NT$0.00 (0.0%)
Hi-Clearance Inc.’s quoted price sits in the lower half of its reported 52-week range, 7.97% below the high.
NT$75.50+NT$0.20 (+0.27%)
Pacific Hospital Supply Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 15.83% below the high.
NT$142.00-NT$3.00 (-2.07%)
Delta Asia International Corporation’s quoted price sits in the lower half of its reported 52-week range, 29.0% below the high.
